Your search for ‘Smart & Biggar’ returned 2,497 results

On March 8, 2019, Justice Fothergill granted Valeant Canada's application for an order prohibiting the Minister of Health from issuing a notice of compliance to Generic Partners for its generic version...

The Patent Prosecution Highway ("PPH") program continues to be a phenomenal success in Canada. It has positioned the country as a highly cost-effective jurisdiction in which to procure patent protection with exceptional speed and efficacy.

Recently, Justice O'Keefe of t­­he Federal Court issued his public Reasons for Judgment concerning a costs award from the liability phase of a patent infringement action between the Dow Chemical Company ("Dow") and NOVA Chemicals Corporation ("Nova"), 2016 FC 91.

This motion arose in the context of a section 8 action in which Apotex claims damages for delay in the issuance of its notice of compliance for its generic lansoprazole product ...

As reported in our June 20, 2014 IP Update, the Government of Canada passed into law Bill C-31, which contains numerous significant amendments to Canada's Trade-marks Act.

There have been two Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations) decisions on the merits so far in 2019 and a pair of appeal decisions

Supreme Court of Canada denies Eli Lilly leave to appeal in olanzapine section 8 damages action.

The Government of Canada has announced that the text of CETA — the Comprehensive Economic and Trade Agreement between Canada and Europe — was finalized after many months of silence on the historic trade deal.

In recent years, the Office québécois de la langue française ("OQLF") and the Quebec Government have tried to force owners of non-French trademarks to add descriptive language in French to their public signs displaying non-French trademarks, ..

CADTH releases 2018-2021 Strategic Plan

In its Common Drug Review (CDR) Update – Issue 133 (with further details in Revisions to CADTH's Biosimilar and Resubmission Processes, Other Administrative Changes...

The Government of Canada has proposed An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, which has passed first reading in the Senate.

On December 18, 2023, the Minister of Health announced the creation of the Canadian Drug Agency. According to the announcement...

Health Canada and the U.S. Food and Drug Administration (FDA) have created a program to support the establishment of a Request for Information Sharing (RIS) program...

In January and February 2026, Health Canada released the Quarterly Report for Q2 2025-2026 (July through September 2025) and for Q3 2025-2026 (October through December 2025).

The Therapeutic Products Directorate (TPD), the Biologic and Radiopharmaceutical Drugs Directorate (BRDD), and the Natural and Non-Prescription Health Products Directorate (NNHPD) ...

In March 2023, the Minister of Health announced the National Strategy for Drugs for Rare Diseases, which has as its objective to increase access to, and affordability of, effective drugs for rare diseases...

The Patented Medicine Prices Review Board (PMPRB) has advised that the new Guidelines will not be implemented on January 1, 2023, and that the Interim Guidance issued by the...